BOSTON, MA, Granata Bio Corporation, a biopharma company, announced its $15M Series A+ funding round.
Granata Bio Corporation, a biopharma company focused on invigorating the $3.6B global infertility medication market, announced its $15M Series A+ funding round. The round was exclusively supported by existing investors, including Gedeon Richter, CooperSurgical, Amboy Street Ventures, and other strategic investors. Granata has raised over $30 million to date.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.